ArticleInteractive journal of medical research2026
The Shifting Landscape of Natural Health Product Licensing in Canada: The e-Commerce Case of Stem Cell Supplements.
Article in Interactive journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unlabelled: Natural health product (NHP) regulations have shifted in Canada, with the aim of reducing "red tape" and enabling market entry. This study assessed how many "stem cell" supplements for sale on Amazon.ca had Health Canada-required natural product number (NPN) licenses compared with vitamin D and "longevity" supplements. It also conducted a marketing overview analysis comparing the Amazon.ca discourse across the 3 product types. Findings show a gap in regulatory licensing compliance between "stem cell" supplements and vitamin D or "longevity" supplements. Marketing discourse also presented potential conflict with regulatory parameters. We discuss the impacts of loosening NHP regulations and the potential for products with weak evidentiary bases to enhance validation through NPN licensing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.